Share-based Payment Arrangement, Expense in USD of ELITE PHARMACEUTICALS INC /NV/ from Q4 2013 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
ELITE PHARMACEUTICALS INC /NV/ quarterly/annual Share-based Payment Arrangement, Expense history and change rate from Q4 2013 to Q3 2025.
  • ELITE PHARMACEUTICALS INC /NV/ Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $49.9K, a 4.61% decline year-over-year.
  • ELITE PHARMACEUTICALS INC /NV/ Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $225K, a 8.87% increase year-over-year.
  • ELITE PHARMACEUTICALS INC /NV/ annual Share-based Payment Arrangement, Expense for 2024 was $228K, a 42.3% increase from 2023.
  • ELITE PHARMACEUTICALS INC /NV/ annual Share-based Payment Arrangement, Expense for 2023 was $160K, a 307% increase from 2022.
  • ELITE PHARMACEUTICALS INC /NV/ annual Share-based Payment Arrangement, Expense for 2022 was $39.3K, a 174% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

ELITE PHARMACEUTICALS INC /NV/ Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $225K $49.9K -$2.41K -4.61% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025
Q2 2025 $228K $52.3K $0 0% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025
Q1 2025 $228K $52.3K $0 0% 01 Jan 2025 31 Mar 2025 10-K 30 Jun 2025
Q4 2024 $228K $70.6K +$20.8K +41.7% 01 Oct 2024 31 Dec 2024 10-Q 13 Feb 2025
Q3 2024 $207K $52.3K +$9.55K +22.3% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025
Q2 2024 $197K $52.3K +$37.3K +249% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025
Q1 2024 $160K $52.3K +$37.3K +249% 01 Jan 2024 31 Mar 2024 10-K 30 Jun 2025
Q4 2023 $123K $49.8K +$36.8K +282% 01 Oct 2023 31 Dec 2023 10-Q 13 Feb 2025
Q3 2023 $85.8K $42.8K +$36.8K +616% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024
Q2 2023 $49K $15K +$9.68K +182% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024
Q1 2023 $39.3K $15K +$11.3K +301% 01 Jan 2023 31 Mar 2023 10-K 01 Jul 2024
Q4 2022 $28.1K $13K +$9.4K +259% 01 Oct 2022 31 Dec 2022 10-Q 14 Feb 2024
Q3 2022 $18.7K $5.97K +$1.8K +43% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023
Q2 2022 $16.9K $5.32K +$2.51K +89.3% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023
Q1 2022 $14.4K $3.74K -$184 -4.69% 01 Jan 2022 31 Mar 2022 10-K 29 Jun 2023
Q4 2021 $14.5K $3.63K +$1.98K +120% 01 Oct 2021 31 Dec 2021 10-Q 14 Feb 2023
Q3 2021 $12.6K $4.18K +$2.09K +99.9% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022
Q2 2021 $10.5K $2.81K -$2.71K -49.1% 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022
Q1 2021 $13.2K $3.92K -$4.66K -54.3% 01 Jan 2021 31 Mar 2021 10-K 29 Jun 2022
Q4 2020 $17.8K $1.65K -$10.2K -86% 01 Oct 2020 31 Dec 2020 10-Q 14 Feb 2022
Q3 2020 $28K $2.09K -$13.4K -86.5% 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021
Q2 2020 $41.4K $5.52K -$20.7K -78.9% 01 Apr 2020 30 Jun 2020 10-Q 16 Aug 2021
Q1 2020 $62.1K $8.58K -$18.1K -67.9% 01 Jan 2020 31 Mar 2020 10-K 14 Jun 2021
Q4 2019 $80.2K $11.8K -$24.7K -67.7% 01 Oct 2019 31 Dec 2019 10-Q 16 Feb 2021
Q3 2019 $105K $15.5K -$21K -57.5% 01 Jul 2019 30 Sep 2019 10-Q 16 Nov 2020
Q2 2019 $126K $26.2K -$10.4K -28.3% 01 Apr 2019 30 Jun 2019 10-Q 14 Aug 2020
Q1 2019 $136K $26.7K -$9.31K -25.8% 01 Jan 2019 31 Mar 2019 10-K 29 Jun 2020
Q4 2018 $146K $36.5K -$1.41K -3.73% 01 Oct 2018 31 Dec 2018 10-Q 10 Feb 2020
Q3 2018 $147K $36.5K -$36.9K -50.2% 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019
Q2 2018 $184K $36.5K -$60.8K -62.5% 01 Apr 2018 30 Jun 2018 10-Q 09 Aug 2019
Q1 2018 $245K $36K -$63K -63.6% 01 Jan 2018 31 Mar 2018 10-K 21 Jun 2019
Q4 2017 $308K $38K -$46.8K -55.2% 01 Oct 2017 31 Dec 2017 10-Q 11 Feb 2019
Q3 2017 $355K $73.4K -$11.4K -13.4% 01 Jul 2017 30 Sep 2017 10-Q 09 Nov 2018
Q2 2017 $366K $97.4K +$7.98K +8.92% 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018
Q1 2017 $358K $99K +$12.1K +14% 01 Jan 2017 31 Mar 2017 10-K 14 Jun 2018
Q4 2016 $346K $84.8K +$9.76K +13% 01 Oct 2016 31 Dec 2016 10-Q 09 Feb 2018
Q3 2016 $336K $84.8K +$3.79K +4.68% 01 Jul 2016 30 Sep 2016 10-Q 09 Nov 2017
Q2 2016 $332K $89.4K -$1.1K -1.21% 01 Apr 2016 30 Jun 2016 10-Q 09 Aug 2017
Q1 2016 $333K $86.9K -$6.53K -6.99% 01 Jan 2016 31 Mar 2016 10-K 14 Jun 2018
Q4 2015 $340K $75K -$14.5K -16.2% 01 Oct 2015 31 Dec 2015 10-Q 09 Feb 2017
Q3 2015 $354K $81K +$27.5K +51.4% 01 Jul 2015 30 Sep 2015 10-Q 09 Nov 2016
Q2 2015 $327K $90.5K +$66.8K +282% 01 Apr 2015 30 Jun 2015 10-Q 09 Aug 2016
Q1 2015 $260K $93.4K 01 Jan 2015 31 Mar 2015 10-K 14 Jun 2017
Q4 2014 $89.5K +$65.8K +278% 01 Oct 2014 31 Dec 2014 10-Q 09 Feb 2016
Q3 2014 $53.5K 01 Jul 2014 30 Sep 2014 10-Q 30 Dec 2015
Q2 2014 $23.7K 01 Apr 2014 30 Jun 2014 10-Q 30 Dec 2015
Q4 2013 $23.7K 01 Oct 2013 31 Dec 2013 10-Q 17 Feb 2015

ELITE PHARMACEUTICALS INC /NV/ Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $228K +$67.6K +42.3% 01 Apr 2024 31 Mar 2025 10-K 30 Jun 2025
2023 $160K +$121K +307% 01 Apr 2023 31 Mar 2024 10-K 30 Jun 2025
2022 $39.3K +$25K +174% 01 Apr 2022 31 Mar 2023 10-K 01 Jul 2024
2021 $14.4K +$1.17K +8.89% 01 Apr 2021 31 Mar 2022 10-K 29 Jun 2023
2020 $13.2K -$48.9K -78.8% 01 Apr 2020 31 Mar 2021 10-K 29 Jun 2022
2019 $62.1K -$74.3K -54.5% 01 Apr 2019 31 Mar 2020 10-K 14 Jun 2021
2018 $136K -$108K -44.3% 01 Apr 2018 31 Mar 2019 10-K 29 Jun 2020
2017 $245K -$113K -31.6% 01 Apr 2017 31 Mar 2018 10-K 21 Jun 2019
2016 $358K +$24.6K +7.38% 01 Apr 2016 31 Mar 2017 10-K 14 Jun 2018
2015 $333K +$73.3K +28.2% 01 Apr 2015 31 Mar 2016 10-K 14 Jun 2018
2014 $260K +$177K +214% 01 Apr 2014 31 Mar 2015 10-K 14 Jun 2017
2013 $82.9K 01 Apr 2013 31 Mar 2014 10-K 15 Jun 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.